These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35247908)

  • 1. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
    Bellmunt J; de Wit R; Fradet Y; Climent MA; Petrylak DP; Lee JL; Fong L; Necchi A; Sternberg CN; O'Donnell PH; Powles T; Plimack ER; Bajorin DF; Balar AV; Castellano D; Choueiri TK; Culine S; Gerritsen W; Gurney H; Quinn DI; Vuky J; Vogelzang NJ; Cristescu R; Lunceford J; Saadatpour A; Loboda A; Ma J; Rajasagi M; Godwin JL; Homet Moreno B; Grivas P
    Clin Cancer Res; 2022 May; 28(10):2050-2060. PubMed ID: 35247908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
    Loi S; Salgado R; Schmid P; Cortes J; Cescon DW; Winer EP; Toppmeyer DL; Rugo HS; De Laurentiis M; Nanda R; Iwata H; Awada A; Tan AR; Sun Y; Karantza V; Wang A; Huang L; Saadatpour A; Cristescu R; Yearley J; Lunceford J; Jelinic P; Adams S
    JCO Precis Oncol; 2023 Apr; 7():e2200317. PubMed ID: 37099733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
    Shitara K; Di Bartolomeo M; Mandala M; Ryu MH; Caglevic C; Olesinski T; Chung HC; Muro K; Goekkurt E; McDermott RS; Mansoor W; Wainberg ZA; Shih CS; Kobie J; Nebozhyn M; Cristescu R; Cao ZA; Loboda A; Özgüroğlu M
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
    Ledermann JA; Shapira-Frommer R; Santin AD; Lisyanskaya AS; Pignata S; Vergote I; Raspagliesi F; Sonke GS; Birrer M; Provencher DM; Sehouli J; Colombo N; González-Martín A; Oaknin A; Ottevanger PB; Rudaitis V; Kobie J; Nebozhyn M; Edmondson M; Sun Y; Cristescu R; Jelinic P; Keefe SM; Matulonis UA
    Gynecol Oncol; 2023 Nov; 178():119-129. PubMed ID: 37862791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
    Gutierrez M; Lam WS; Hellmann MD; Gubens MA; Aggarwal C; Tan DSW; Felip E; Chiu JWY; Lee JS; Yang JC; Garon EB; Finocchiaro G; Ahn MJ; Luft A; Landers GA; Basso A; Ma H; Kobie J; Palcza J; Cristescu R; Fong L; Snyder A; Yuan J; Herbst RS
    Nat Med; 2023 Jul; 29(7):1718-1727. PubMed ID: 37429923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
    Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers predictive of response to pembrolizumab in head and neck cancer.
    Pfister DG; Haddad RI; Worden FP; Weiss J; Mehra R; Chow LQM; Liu SV; Kang H; Saba NF; Wirth LJ; Sukari A; Massarelli E; Ayers M; Albright A; Webber AL; Mogg R; Lunceford J; Huang L; Cristescu R; Cheng J; Seiwert TY; Bauml JM
    Cancer Med; 2023 Mar; 12(6):6603-6614. PubMed ID: 36479637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
    Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
    Fradet Y; Bellmunt J; Vaughn DJ; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Nam K; Frenkl TL; Perini RF; de Wit R; Bajorin DF
    Ann Oncol; 2019 Jun; 30(6):970-976. PubMed ID: 31050707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
    Galsky MD; Saci A; Szabo PM; Han GC; Grossfeld G; Collette S; Siefker-Radtke A; Necchi A; Sharma P
    Clin Cancer Res; 2020 Oct; 26(19):5120-5128. PubMed ID: 32532789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.
    Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Caglevic C; Chung HC; Muro K; Van Cutsem E; Kobie J; Cristescu R; Aurora-Garg D; Lu J; Shih CS; Adelberg D; Cao ZA; Fuchs CS
    Ann Oncol; 2021 Sep; 32(9):1127-1136. PubMed ID: 34082019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
    Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
    Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.